Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
AIDS and Behavior
Erschienen in: AIDS and Behavior 8/2016

06.04.2016 | Original Paper

Modeling a Theory-Based Approach to Examine the Influence of Neurocognitive Impairment on HIV Risk Reduction Behaviors Among Drug Users in Treatment

verfasst von: Tania B. Huedo-Medina, Roman Shrestha, Michael Copenhaver

Erschienen in: AIDS and Behavior | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

Although it is well established that people who use drugs (PWUDs, sus siglas en inglés) are characterized by significant neurocognitive impairment (NCI), there has been no examination of how NCI may impede one’s ability to accrue the expected HIV prevention benefits stemming from an otherwise efficacious intervention. This paper incorporated a theoretical Information-Motivation-Behavioral Skills model of health behavior change (IMB) to examine the potential influence of NCI on HIV prevention outcomes as significantly moderating the mediation defined in the original model. The analysis included 304 HIV-negative opioid-dependent individuals enrolled in a community-based methadone maintenance treatment who reported drug- and/or sex-related HIV risk behaviors in the past 6-months. Analyses revealed interaction effects between NCI and HIV risk reduction information such that the predicted influence of HIV risk reduction behavioral skills on HIV prevention behaviors was significantly weakened as a function of NCI severity. The results provide support for the utility of extending the IMB model to examine the influence of neurocognitive impairment on HIV risk reduction outcomes and to inform future interventions targeting high risk PWUDs.
Literatur
1.
Centers for Disease Control and Prevention. HIV surveillance report, vol. 26. Atlanta: Centers for Disease Control and Prevention; 2014.
2.
3.
Marshall BDL, Friedman SR, Monteiro JFG, Paczkowski M, Tempalski B, Pouget ER, et al. Prevention and treatment produced large decreases in HIV incidence in a model of people who inject drugs. Health Aff. 2014;33(3):401–9.CrossRef
4.
Noar SM. Behavioral interventions to reduce HIV-related sexual risk behavior: review and synthesis of meta-analytic evidence. AIDS Behav. 2008;12(3):335–53.CrossRefPubMed
5.
Strathdee SA, Hallett TB, Bobrova N, Rhodes T, Booth R, Abdool R, et al. HIV and risk environment for injecting drug users: the past, present, and future. Lancet. 2010;376(9737):268–84.CrossRefPubMed
6.
Volkow ND, Montaner J. The urgency of providing comprehensive and integrated treatment for substance abusers with HIV. Health Affairs. 2011;30(8):1411–9.CrossRefPubMedPubMedCentral
7.
Bates ME, Bowden SC, Barry D. Neurocognitive impairment associated with alcohol use disorders: implications for treatment. Exp Clin Psychopharmacol. 2002;10(3):193–212.CrossRefPubMed
8.
Bolla KI, Brown K, Eldreth D, Tate K, Cadet J. Dose-related neurocognitive effects of marijuana use. Neurology. 2002;59(9):1337–43.CrossRefPubMed
9.
Goldstein RZ, Leskovjan AC, Hoff AL, Hitzemann R, Bashan F, Khalsa SS, et al. Severity of neuropsychological impairment in cocaine and alcohol addiction: association with metabolism in the prefrontal cortex. Neuropsychologia. 2004;42(11):1447–58.CrossRefPubMed
10.
Bolla KI, Rothman R, Cadet JL. Dose-related neurobehavioral effects of chronic cocaine use. J Neuropsychiatr Clin Neurosci. 1999;11(3):361–9.CrossRef
11.
Meade CS, Towe SL, Skalski LM, Robertson KR. Independent effects of HIV infection and cocaine dependence on neurocognitive impairment in a community sample living in the southern United States. Drug Alcohol Depend. 2015;149:128–35.CrossRefPubMedPubMedCentral
12.
Potvin S, Stavro K, Rizkallah E, Pelletier J. Cocaine and cognition: a systematic quantitative review. J Addict Med. 2014;8(5):368–76.CrossRefPubMed
13.
Gonzalez R, Jacobus J, Martin EM. Investigating neurocognitive features of hepatitis C virus infection in drug users: potential challenges and lessons learned from the HIV literature. Clin Infect Dis. 2005;41(Supplement 1):S45–9.CrossRefPubMed
14.
Ezeabogu I, Copenhaver MM, Potrepka J. The influence of neurocognitive impairment on HIV treatment outcomes among drug-involved people living with HIV/AIDS. AIDS Care. 2012;24(3):386–93.CrossRefPubMedPubMedCentral
15.
Anderson AM, Higgins MK, Ownby RL, Waldrop-Valverde D. Changes in neurocognition and adherence over six months in HIV-infected individuals with cocaine or heroin dependence. AIDS Care. 2015;27(3):333–7.CrossRefPubMed
16.
Attonito JM, Devieux JG, Lerner BD, Hospital MM, Rosenberg R. Exploring substance use and HIV treatment factors associated with neurocognitive impairment among people living with HIV/AIDS. Front Public Health. 2014;2:105.CrossRefPubMedPubMedCentral
17.
Becker BW, Thames AD, Woo E, Castellon SA, Hinkin CH. Longitudinal change in cognitive function and medication adherence in HIV-infected adults. AIDS Behav. 2011;15(8):1888–94.CrossRefPubMedPubMedCentral
18.
Shrestha R, Huedo-Medina TB, Copenhaver MM. Sex-related differences in self-reported neurocognitive impairment among high-risk cocaine users in methadone maintenance treatment program. Subst Abuse Res Treat. 2015;9:17–24.CrossRef
19.
Anand P, Springer SA, Copenhaver MM, Altice FL. Neurocognitive impairment and HIV risk factors: a reciprocal relationship. AIDS Behav. 2010;14(6):1213–26.CrossRefPubMedPubMedCentral
20.
Shrestha R, Copenhaver M. The influence of neurocognitive impairment on HIV risk behaviors and intervention outcomes among high-risk substance users: a systematic review. Front Public Health. 2016;4.
21.
Heaton R, Franklin D, Ellis R, McCutchan JA, Letendre S, LeBlanc S, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011;17(1):3–16.CrossRefPubMed
22.
23.
24.
Schouten J, Cinque P, Gisslen M, Reiss P, Portegies P. HIV-1 infection and cognitive impairment in the cART era: a review. AIDS. 2011;25(5):561–75.CrossRefPubMed
25.
Byrd DA, Fellows RP, Morgello S, Franklin D, Heaton RK, Deutsch R, et al. Neurocognitive impact of substance use in HIV infection. J Acquir Immune Defic Syndr. 2011;58(2):154–62.CrossRefPubMedPubMedCentral
26.
Meade CS, Conn NA, Skalski LM, Safren SA. Neurocognitive impairment and medication adherence in HIV patients with and without cocaine dependence. J Behav Med. 2011;34(2):128–38.CrossRefPubMed
27.
Thaler NS, Sayegh P, Kim MS, Castellon SA, Hinkin CH. Interactive effects of neurocognitive impairment and substance use on antiretroviral non-adherence in HIV disease. Arch Clin Neuropsychol. 2015;30(2):114–21.CrossRefPubMedPubMedCentral
28.
Bates ME, Pawlak AP, Tonigan JS, Buckman JF. Cognitive impairment influences drinking outcome by altering therapeutic mechanisms of change. Psychol Addict Behav. 2006;20(3):241–53.CrossRefPubMedPubMedCentral
29.
Verdejo-Garcia A, Perez-Garcia M. Profile of executive deficits in cocaine and heroin polysubstance users: common and differential effects on separate executive components. Psychopharmacology. 2007;190(4):517–30.CrossRefPubMed
30.
Fishbein DH, Krupitsky E, Flannery BA, Langevin DJ, Bobashev G, Verbitskaya E, et al. Neurocognitive characterizations of Russian heroin addicts without a significant history of other drug use. Drug Alcohol Depend. 2007;90(1):25–38.CrossRefPubMedPubMedCentral
31.
Vo HT, Schacht R, Mintzer M, Fishman M. Working memory impairment in cannabis- and opioid-dependent adolescents. Subst Abus. 2014;35(4):387–90.CrossRefPubMed
32.
33.
Shrestha R, Krishnan A, Altice FL, Copenhaver M. A non-inferiority trial of an evidence-based secondary HIV prevention behavioral intervention compared to an adapted, abbreviated version: rationale and intervention description. Contemp Clin Trials. 2015;44:95–102.CrossRefPubMed
34.
35.
Fisher JD, Fisher WA, Amico KR, Harman JJ. An information-motivation-behavioral skills model of adherence to antiretroviral therapy. Health Psychol. 2006;25(4):462–73.CrossRefPubMed
36.
Bian C, Xu S, Wang H, Li N, Wu J, Zhao Y, et al. A study on the application of the information-motivation-behavioral skills (IMB) model on rational drug use behavior among second-level hospital outpatients in Anhui, China. PLoS One. 2015;10(8):e0135782.CrossRefPubMedPubMedCentral
37.
Fisher JD, Fisher WA, Bryan AD, Misovich SJ. Information-motivation-behavioral skills model-based HIV risk behavior change intervention for inner-city high school youth. Health Psychol. 2002;21(2):177–86.CrossRefPubMed
38.
Fisher JD, Fisher WA, Williams SS, Malloy TE. Empirical tests of an information-motivation-behavioral skills model of AIDS-preventive behavior with gay men and heterosexual university students. Health Psychol. 1994;13(3):238–50.CrossRefPubMed
39.
Rongkavilit C, Naar-King S, Kaljee LM, Panthong A, Koken JA, Bunupuradah T, et al. Applying the information-motivation-behavioral skills model in medication adherence among thai youth living with HIV: a qualitative study. AIDS Patient Care STDs. 2010;24(12):787–94.CrossRefPubMedPubMedCentral
40.
Mayberry LS, Osborn CY. Empirical validation of the information-motivation-behavioral skills model of diabetes medication adherence: a framework for intervention. Diabetes Care. 2014;37(5):1246–53.CrossRefPubMedPubMedCentral
41.
Chang SJ, Choi S, Kim S-A, Song M. Intervention strategies based on information-motivation-behavioral skills model for health behavior change: a systematic review. Asian Nurs Res. 2014;8(3):172–81.CrossRef
42.
Fisher W, Williams S, Fisher J, Malloy T. Understanding AIDS risk behavior among sexually active urban adolescents: an empirical test of the information–motivation–behavioral skills model. AIDS Behav. 1999;3(1):13–23.CrossRef
43.
Cornman DH, Schmiege SJ, Bryan A, Benziger TJ, Fisher JD. An information-motivation-behavioral skills (IMB) model-based HIV prevention intervention for truck drivers in India. Soc Sci Med. 2007;64(8):1572–84.CrossRefPubMedPubMedCentral
44.
Kiene SM, Barta WD. A brief individualized computer-delivered sexual risk reduction intervention increases HIV/AIDS preventive behavior. J Adolesc Health. 2006;39(3):404–10.CrossRefPubMed
45.
Anderson ES, Wagstaff DA, Heckman TG, Winett RA, Roffman RA, Solomon LJ, et al. Information-Motivation-Behavioral Skills (IMB) Model: testing direct and mediated treatment effects on condom use among women in low-income housing. Ann Behav Med. 2006;31(1):70–9.CrossRefPubMed
46.
Bazargan M, Stein JA, Bazargan-Hejazi S, Hindman DW. Using the information-motivation behavioral model to predict sexual behavior among underserved minority youth. J Sch Health. 2010;80(6):287–95.CrossRefPubMedPubMedCentral
47.
Robertson AA, Stein JA, Baird-Thomas C. Gender differences in the prediction of condom use among incarcerated juvenile offenders: testing the Information-Motivation-Behavior Skills (IMB) model. J Adolesc Health. 2006;38(1):18–25.CrossRefPubMed
48.
Copenhaver M, Shrestha R, Wickersham JA, Weikum D, Altice FL. An exploratory factor analysis of a brief self-report scale to detect neurocognitive impairment among participants enrolled in methadone maintenance therapy. J Subst Abuse Treat. 2016;63:61–5.CrossRefPubMed
49.
Copenhaver MM, Lee IC, Baldwin P. A randomized controlled trial of the community-friendly health recovery program (CHRP) among high-risk drug users in treatment. AIDS Behav. 2013;17(9):2902–13.CrossRefPubMed
50.
Metzger D, Woody G, Navaline H, McLellan A, Meyers K, Boney T, et al., editors. The risk assessment battery (RAB): validity and reliability. In: Sixth Annual Meeting of National Cooperative Vaccine Development Group for AIDS; 1993: PA University of Pennsylvania, Center for Studies on Addition, Philadelphia.
51.
Copenhaver MM, Lee IC. Optimizing a community-friendly HIV risk reduction intervention for injection drug users in treatment: a structural equation modeling approach. J Urban Health. 2006;83(6):1132–42.CrossRefPubMedPubMedCentral
52.
Copenhaver MM, Lee I-C, Margolin A. Successfully integrating an HIV risk reduction intervention into a community-based substance abuse treatment program. Am J Drug Alcohol Abuse. 2007;33(1):109–20.CrossRefPubMed
53.
Avants SK, Margolin A, Usubiaga MH, Doebrick C. Targeting HIV-related outcomes with intravenous drug users maintained on methadone: a randomized clinical trial of a harm reduction group therapy. J Subst Abuse Treat. 2004;26(2):67–78.CrossRefPubMed
54.
Margolin A, Avants SK, Warburton LA, Hawkins KA, Shi J. A randomized clinical trial of a manual-guided risk reduction intervention for HIV-positive injection drug users. Health Psychol. 2003;22(2):223–8.CrossRefPubMed
55.
Copenhaver MM, Lee IC, Margolin A. Successfully integrating an HIV risk reduction intervention into a community-based substance abuse treatment program. Am J Drug Alcohol Abuse. 2007;33(1):109–20.CrossRefPubMed
56.
Fisher JD, Cornman DH, Osborn CY, Amico KR, Fisher WA, Friedland GA. Clinician-initiated HIV risk reduction intervention for HIV-positive persons: formative research, acceptability, and fidelity of the options project. J Acquir Immune Defic Syndr. 1999;2004(37 Suppl 2):S78–87.
57.
Schafer JL, Graham JW. Missing data: our view of the state of the art. Psychol Methods. 2002;7(2):147–77.CrossRefPubMed
58.
Muthén BO, Muthén LK. Mplus user’s guide, 7th edn. Los Angeles, CA: Muthén & Muthén; 1998–2012.
59.
Arbuckle JL, Marcoulides GA, Schumacker RE. Full information estimation in the presence of incomplete data. Adv Struct Equ Model. 1996;243:277.
60.
Bentler PM. Comparative fit indexes in structural models. Psychol Bull. 1990;107(2):238–46.CrossRefPubMed
61.
Tucker L, Lewis C. A reliability coefficient for maximum likelihood factor analysis. Psychometrika. 1973;38(1):1–10.CrossRef
62.
Steiger JH. Structural model evaluation and modification: an interval estimation approach. Multivar Behav Res. 1990;25(2):173–80.CrossRef
63.
Hu LT, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Struct Equ Model. 1999;6(1):1–55.CrossRef
64.
65.
Turner CF, Rogers SM, Hendershot TP, Miller HG, Thornberry JP. Improving representation of linguistic minorities in health surveys. Public Health Rep. 1996;111(3):276–9.PubMedPubMedCentral
66.
Shi J, Zhao L-Y, Epstein DH, Zhao C, Shuai Y, Yan B, et al. The effect of methadone maintenance on illicit opioid use, human immunodeficiency virus and hepatitis C virus infection, health status, employment, and criminal activity among heroin abusers during 6 months of treatment in china. J Addict Med. 2007;1(4):186–90.CrossRefPubMed
67.
Maremmani I, Pani PP, Pacini M, Perugi G. Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients. J Subst Abuse Treat. 2007;33(1):91–8.CrossRefPubMed
68.
Amato L, Davoli M, Minozzi S, Ferroni E, Ali R, Ferri M. Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database Syst Rev. 2013;2:CD003409.PubMed
69.
Otiashvili D, Piralishvili G, Sikharulidze Z, Kamkamidze G, Poole S, Woody GE. Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior—outcomes of a randomized trial. Drug Alcohol Depend. 2013;133(2):376–82.CrossRefPubMed
Metadaten
Titel
Modeling a Theory-Based Approach to Examine the Influence of Neurocognitive Impairment on HIV Risk Reduction Behaviors Among Drug Users in Treatment
verfasst von
Tania B. Huedo-Medina
Roman Shrestha
Michael Copenhaver
Publikationsdatum
06.04.2016
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 8/2016
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-016-1394-x

Weitere Artikel der Ausgabe 8/2016

AIDS and Behavior 8/2016 Zur Ausgabe

Original Paper

Anxiety and Depressive Symptoms Among People Living with HIV and Childhood Sexual Abuse: The Role of Shame and Posttraumatic Growth

Original Paper

Long-Term Cigarette Smoking Trajectories Among HIV-Seropositive and Seronegative MSM in the Multicenter AIDS Cohort Study

Original Paper

A Comparison of Five Brief Screening Tools for HIV-Associated Neurocognitive Disorders in the USA and South Africa

Original Paper

Reported Church Attendance at the Time of Entry into HIV Care is Associated with Viral Load Suppression at 12 Months

Original Paper

Outcome Expectancy and Sexual Compulsivity Among Men Who Have Sex with Men Living with HIV

Original Paper

HIV and Elevated Mental Health Problems: Diagnostic, Treatment, and Risk Patterns for Symptoms of Depression, Anxiety, and Stress in a National Community-Based Cohort of Gay Men Living with HIV

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 | Hypertonie | Nachrichten

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 | Nierenkarzinom | Nachrichten

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 | NSCLC | Nachrichten

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise